Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.

ABSTRACT:

Background

Romidepsin is a structurally unique histone deacetylase inhibitor approved by the U.S. Food and Drug Administration for therapy of relapsed or refractory cutaneous T-cell lymphoma (CTCL). Localized electron beam radiation therapy (LEBT) is standard practice in the care of patients with chronically traumatized and painful lesions. Combination therapy of those two modalities may be beneficial for the therapy of CTCL.

Objectives

To report observations on supportive LEBT utilized for isolated refractory lesions in patients on romidepsin.

Methods

Observations were made during a phase II clinical trial sponsored by the National Cancer Institute (NCI-1312) examining the efficacy of romidepsin for patients with relapsed, refractory or advanced CTCL, stage IB-IVA my

SUBMITTER: Akilov OE 

PROVIDER: S-EPMC3386371 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature